Trending...
- Tips for Skin Care During the Winter Months
- Saya International Corporation Announces Appointment of Sheida Chumba to its Board of Directors
- George Harrison's Seminal 1970 Solo Album 'All Things Must Pass' Celebrated With New Stereo Mix Of Legendary Title Track On Its 50th Anniversary
HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced that eight clinical abstracts evaluating the use of its novel technology were accepted for presentation during the virtual American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, Oct. 24-28.
"We are thrilled to have eight abstracts from leading academic clinicians highlighting our technology," said Sean Shirvani, M.D., senior vice president of Clinical and Medical Affairs at RefleXion. "The presentations will share new data on the potential of BgRT for targeting tumors in diverse anatomic locations and from varied histologies, including non-small cell lung, prostate and pancreatic cancers. The investigations also explore the exciting opportunity of leveraging PET information as a future biomarker with BgRT.
More on The Californer
"Through our clinical partnerships, we continue to produce comprehensive, evidence-based research that builds on the strong foundation of previously published studies," continued Shirvani. "We believe the RefleXion X1 can form the backbone of any radiotherapy clinic, as it delivers IMRT/SBRT/SRS and unlocks opportunities for procedural growth with BgRT in local and metastatic disease."
The following presentations taking place during ASTRO 2020 evaluate RefleXion's novel technology:
Sunday, Oct 25, 2:15 PM. Poster Session 02, Poster Hall:
Monday, Oct 26, 12:20 PM Physics 06 – Imaging and Response Assessment:
Tuesday, Oct 27:
More on The Californer
About RefleXion Medical
RefleXion is a privately-held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
*The RefleXion X1 BgRT capability requires 510(k) clearance; this feature is not available for sale.
"We are thrilled to have eight abstracts from leading academic clinicians highlighting our technology," said Sean Shirvani, M.D., senior vice president of Clinical and Medical Affairs at RefleXion. "The presentations will share new data on the potential of BgRT for targeting tumors in diverse anatomic locations and from varied histologies, including non-small cell lung, prostate and pancreatic cancers. The investigations also explore the exciting opportunity of leveraging PET information as a future biomarker with BgRT.
More on The Californer
- CLARA Analytics Unveils Its AI-Based Litigation Avoidance Solution for Commercial Auto
- Shero Comics' Cheerleading Comic, Squad Goals, Debuts as #1 Amazon Best Seller
- California: Governor Newsom Announces Appointments 12.2.20
- San Jose: FLASH REPORT #139 - COVID-19 Response and Recovery
- Quantum Integration's Internet of Things Platform Receives Warm Reception From Early Supporters
"Through our clinical partnerships, we continue to produce comprehensive, evidence-based research that builds on the strong foundation of previously published studies," continued Shirvani. "We believe the RefleXion X1 can form the backbone of any radiotherapy clinic, as it delivers IMRT/SBRT/SRS and unlocks opportunities for procedural growth with BgRT in local and metastatic disease."
The following presentations taking place during ASTRO 2020 evaluate RefleXion's novel technology:
Sunday, Oct 25, 2:15 PM. Poster Session 02, Poster Hall:
- 2686 "Simultaneous Integrated Boost of Lung Tumors in the Stereotactic Ablative Setting using BgRT Tracked Delivery"
- 2831 "Use of a Detailed Process Map for Clinical Workflow of a New Biology-guided Radiotherapy (BgRT) Machine"
- 2768 "Feasibility of Biology-Guided Radiotherapy for Pancreatic Tumors: An Assessment of Normalized Target SUV"
Monday, Oct 26, 12:20 PM Physics 06 – Imaging and Response Assessment:
- SS 21 – "Increased 18F-FDG Metabolic Activity During Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs"
Tuesday, Oct 27:
More on The Californer
- Triumph Tech Achieves AWS DevOps Competency
- Governor Newsom Statement on Death of California Highway Patrol Officer 12.2.20
- Granite Awarded $16 Million Airport Refueling Facility Project in San Diego
- Shero Comics' Cheerleading Comic, Squad Goals, Debuts as #1 Amazon Best Seller
- Supreme Court Rules There Is No Santa Claus In New Holiday Book
- 3:15 PM QP-19 – Physics – Motion Management "Feasibility of Biology-guided Radiotherapy (BgRT) Targeting FDG Avid Liver Metastases"
- 2:00 PM 2268 PV 06 Poster "FDG-PET Metrics in Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis"
- 2:00 PM 2258 PV 06 Poster "Prognostic Value of FDG-PET Metrics for Advanced NSCLC Patients Treated with First-line Immunotherapy"
About RefleXion Medical
RefleXion is a privately-held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
*The RefleXion X1 BgRT capability requires 510(k) clearance; this feature is not available for sale.
Filed Under: Business
0 Comments
Latest on The Californer
- Berkshire Hathaway Homeservices Hilton Head Bluffton Realty Taps Christina Galbreath-Gonzalez To Lead Bluffton Office
- Robert T. Ball, Jr., MD Honored with ReadyCommunities Partnership/CCROA 2020 National Service Award For Leadership in SC Communities Amidst Pandemic
- Introducing Salesforce Hyperforce
- Gupshup Launches a New Messaging Channel, GIP, to Enhance Business Communications with Consumers
- Australian Artist seeks 4 Million USD in damages from Bollywood
- Micro Magic, Inc. Delivers World's Highest Performance/Power RISC-V Core
- Bidgely Recognized by NARUC for Enhancing Gas Utility Customer Engagement and Energy Efficiency Through Artificial Intelligence
- San Jose: Notice of CEQA Posting: Initial Study/Addendum for Delmas Senior Living Project
- Vesper Public Relations Pushes Through A Year of Panic & Pandemic spreading their client's messages
- Scali Rasmussen Recognized as a 'Most Admired Law Firm' by the Los Angeles Business Journal
- California: Governor Newsom Announces Appointments 12.1.20
- Reigning National Football League's DPOY, Stephon Gilmore, Hand Writes a Note to his Five-Year Old Son, Addressing Why "Black Lives Matter"
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cabot Oil & Gas Corporation and Encourages Investors with Losses to Contact the Firm
- 12 Days of Vallejo Photo Contest
- As Holiday Cases Rise, Chris Mann's New Viral Smash, "the 12 Days Of Quarantine," Reminds Us Where We Began
- Governor Newsom Releases the Master Plan for Early Learning and Care: California for All Kids
- Outer Aisle Expands New Distribution in Major Retailers Nationwide
- Chipotle Mexican Grill To Announce Fourth Quarter And Full Year 2020 Results On February 2, 2021
- Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
- San Jose: San José Mayor Statement on Thanksgiving Gathering